, (GLOBE NEWSWIRE) -- (NASDAQ:TINY), an investor in transformative companies enabled by disruptive science, notes the announcement by its portfolio company, , of the launch of to develop small molecule inhibitors for the treatment of cancer and metabolic diseases in alliance with Weill Cornell Medicine. Petra Pharma's co-founders, , Ph.D. and , Ph.D., are researchers who have contributed to numerous breakthrough advances in cancer. Under Accelerator's investment and operations management model, the early operations of Petra Pharma will be overseen by Accelerator's core management team. Accelerator's announcement can be viewed at http://petrapharmacorp.com/wp-content/uploads/2016/01/Petra-Pharma-Series-A-Financing_Final.pdf.
About
is a publicly traded venture capital firm that is also a business development company. Detailed information about and its holdings can be found on its website at www.HHVC.com, on Facebook at www.facebook.com/harrisharrisvc and by following on Twitter @harrisandharrisgroup.
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K for the fiscal year ended , as well as subsequent filings, filed with the for a more detailed discussion of the risks and uncertainties associated with the Company's business, including, but not limited to, the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The references and links to the websites www.HHVC.com, http://petrapharmacorp.com and www.Facebook.com have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. is not responsible for the contents of third party websites.
Press Contact:
212-582-0900
Source:
News Provided by Acquire Media
Close window | Back to top
Harris & Harris Group Inc. issued this content on 2016-01-06 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 2016-01-06 17:35:04 UTC
Original Document: http://ir.hhvc.com/releasedetail.cfm?ReleaseID=949137
180 Degree Capital Corp. is a non-diversified closed-end management investment company. The Company operates as an internally managed investment company. The Companyâs investment objective is to generate capital appreciation and current income from investments and investment-related activities such as managed funds and accounts. The Company invests its assets in various industries, including advertising, application software, asset management and custody banks, biotechnology, communications equipment, construction machinery and heavy trucks, electronic manufacturing services, fertilizers and agricultural chemicals, health care equipment, health care technology, interactive media and services, pharmaceuticals, restaurants, specialized finance, specialty chemicals, technology hardware, storage and peripherals, trading companies and distributors, miscellaneous common stocks industries, steel and apparel, accessories and luxury goods.
HARRIS & HARRIS GROUP, INC. 
